生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展

doi:10.35541/cjd.20191176

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (1): 72-75.doi: 10.35541/cjd.20191176

生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展

高蓉¹ 张兰² 李政霄¹

¹西安交通大学第二附属医院皮肤病院，西安 710004；²西安交通大学第一附属医院东院皮肤科，西安 710089

收稿日期:2019-12-23 修回日期:2021-06-17 发布日期:2021-12-31
通讯作者: 李政霄 E-mail:lizhengxiao1979@163.com

Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis

Gao Rong¹, Zhang Lan², Li Zhengxiao¹

¹Department of Dermatology, The Second Affiliated Hospital of Xi′an Jiaotong University, Xi′an 710004, China; ²Department of Dermatology, East Hospital of the First Affiliated Hospital of Xi′an Jiaotong University, Xi′an 710089, China

Received:2019-12-23 Revised:2021-06-17 Published:2021-12-31
Contact: Li Zhengxiao E-mail:lizhengxiao1979@163.com

摘要/Abstract

摘要： 【摘要】银屑病是一种免疫介导的慢性复发性炎症性疾病，针对其发病机制中细胞因子及受体的生物制剂近年成为银屑病重要的治疗手段。随着司库奇尤单抗（secukinumab）和乌司奴单抗（ustekinumab）等生物制剂在我国陆续上市，生物制剂在银屑病治疗中的应用将越来越普遍。本文综述不同生物制剂治疗中重度斑块状银屑病及关节病型银屑病的疗效及个体化用药选择，以期为医师临床用药提供参考。

关键词: 银屑病, 生物制剂, 肿瘤坏死因子α, 白细胞介素类, 治疗结果, 中重度斑块状银屑病, 关节病型银屑病

Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic recurrent inflammatory disease, and biological agents targeting cytokines and their receptors involved in its pathogenesis have become an increasingly important option for its treatment in recent years. With the successive appearance of biological agents such as secukinumab and ustekinumab on the market in China, the use of biologics will become increasingly common in the treatment of psoriasis. This review summarizes the efficacy of different biological agents and individualized drug selection in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, with a view to providing a reference for physicians in clinical practice.

Key words: Psoriasis, Biological agents, Tumor necrosis factor?alpha, Interleukin?17, Interleukins, Treatment outcome, Moderate to severe plaque psoriasis

高蓉张兰李政霄. 生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展[J]. 中华皮肤科杂志, 2022,55(1):72-75. doi:10.35541/cjd.20191176

Gao Rong, Zhang Lan, Li Zhengxiao. Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis[J]. Chinese Journal of Dermatology, 2022, 55(1): 72-75.doi:10.35541/cjd.20191176

参考文献 29

［1］	Gisondi P, Geat D, Pizzolato M, et al. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis［J］. Curr Opin Pharmacol, 2019,46:90⁃99. doi: 10.1016/j.coph.2019.05.007.
［2］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［3］	Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics ［J］. J Am Acad Dermatol, 2019, 80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
［4］	Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2017,376（16）:1551⁃1560. doi: 10.1056/NEJMoa1607017.
［5］	Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate⁃to⁃severe plaque psoriasis up to 1 year: results from the CLEAR study［J］. J Am Acad Dermatol, 2017,76（1）:60⁃69.e9. doi: 10.1016/j.jaad.2016.08.008.
［6］	Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate⁃to⁃severe psoriasis （UNCOVER⁃2 and UNCOVER⁃3）: results from two phase 3 randomised trials［J］. Lancet, 2015,386（9993）:541⁃551. doi: 10.1016/S0140⁃6736（15）60125⁃8.
［7］	Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials［J］. Br J Dermatol, 2019,180（2）:306⁃314. doi: 10.1111/bjd.17318.
［8］	Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12⁃week randomized, double⁃blinded, placebo⁃controlled phase 2b trial［J］. J Am Acad Dermatol, 2018,79（2）:277⁃286.e10. doi: 10.1016/j.jaad.2018.03.037.
［9］	Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate⁃to⁃severe plaque psoriasis （UltIMMa⁃1 and UltIMMa⁃2）: results from two double⁃blind, randomised, placebo⁃controlled and ustekinumab⁃controlled phase 3 trials［J］. Lancet, 2018,392（10148）:650⁃661. doi: 10.1016/S0140⁃6736（18）31713⁃6.
［10］	Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis （reSURFACE 1 and reSURFACE 2）: results from two randomised controlled, phase 3 trials［J］. Lancet, 2017,390（10091）:276⁃288. doi: 10.1016/S0140⁃6736（17）31279⁃5.
［11］	Reich K, Rich P, Maari C, et al. Efficacy and safety of mirikizumab （LY3074828） in the treatment of moderate⁃to⁃severe plaque psoriasis: results from a randomized phase II study［J］. Br J Dermatol, 2019,181（1）:88⁃95. doi: 10.1111/bjd.17628.
［12］	Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate⁃to⁃severe plaque psoriasis［J］. Br J Dermatol, 2018,178（2）:509⁃519. doi: 10.1111/bjd.16102.
［13］	Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd.19039.
［14］	Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management［J］. J Am Acad Dermatol, 2017,76（3）:393⁃403. doi: 10.1016/j.jaad.2016.07.065.
［15］	Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin⁃17 inhibition: role in psoriasis and inflammatory bowel disease［J］. J Dermatolog Treat, 2018,29（1）:13⁃18. doi: 10.1080/09546634. 2017.1329511.
［16］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物治疗专家共识（2019）［J］.中华皮肤科杂志,2019,52（12）:863⁃871. doi: 10.35541/cjd.20190892.
［17］	Amin M, No DJ, Egeberg A, et al. Choosing first⁃line biologic treatment for moderate⁃to⁃severe psoriasis: what does the evidence say?［J］. Am J Clin Dermatol, 2018,19（1）:1⁃13. doi: 10.1007/s40257⁃017⁃0328⁃3.
［18］	Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis （the 2019 version）［J］. J Dermatol, 2020,47（3）:201⁃222. doi: 10.1111/1346⁃8138.15196.
［19］	Torgutalp M, Poddubnyy D. Emerging treatment options for spondyloarthritis ［J］. Best Pract Res Clin Rheumatol, 2018, 32（3）:472⁃484. doi: 10.1016/j.berh.2019.01.014.
［20］	Raychaudhuri SP, Wilken R, Sukhov AC, et al. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies［J］. J Autoimmun, 2017,76:21⁃37. doi: 10.1016/j.jaut.2016.10.009.
［21］	Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin⁃17A specific monoclonal antibody, for the treatment of biologic⁃naive patients with active psoriatic arthritis: results from the 24⁃week randomised, double⁃blind, placebo⁃controlled and active （adalimumab）⁃controlled period of the phase III trial SPIRIT⁃P1［J］. Ann Rheum Dis, 2017,76（1）:79⁃87. doi: 10.1136/annrheumdis⁃2016⁃209709.
［22］	Van den Bosch F, Coates L. Clinical management of psoriatic arthritis［J］. Lancet, 2018,391（10136）:2285⁃2294. doi: 10.1016/S0140⁃6736（18）30949⁃8.
［23］	McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double⁃blind, placebo⁃controlled PSUMMIT 1 trial［J］. Lancet, 2013,382（9894）:780⁃789. doi: 10.1016/S0140⁃6736（13）60594⁃2.
［24］	Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double⁃blind, phase III FUTURE 5 study［J］. Ann Rheum Dis, 2018,77（6）:890⁃897. doi: 10.1136/annrheumdis⁃2017⁃212687.
［25］	Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti⁃IL17RA monoclonal antibody, in psoriatic arthritis［J］. N Engl J Med, 2014,370（24）:2295⁃2306. doi: 10.1056/NEJMoa1315231.
［26］	Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic⁃naive or had previously received TNFα inhibitor treatment （DISCOVER⁃1）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1115⁃1125. doi: 10.1016/S0140⁃6736（20）30265⁃8.
［27］	刘鸿伟, 胡雪英, 雷东春, 等. 阿达木单抗治疗重度斑块状银屑病的临床观察［J］.中华皮肤科杂志,2020,53（9）:744⁃746. doi: 10.35541/cjd.20190757.
［28］	朱晨雨, 孙秋宁, 舒畅, 等. 英夫利西单抗治疗重度银屑病17例临床观察［J］.中华皮肤科杂志,2016,49（4）:294⁃295. doi: 10.3760/cma.j.issn.0412⁃4030.2016.04.021.
［29］	Huang H, Cai ML, Hong XJ, et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients［J］. Eur J Dermatol, 2020,30（5）:554⁃560. doi: 10.1684/ejd.2020.3878.

[1]	丁瑞张卫亮李静陈羽佳李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429.
[2]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[3]	吴玉冰王晓宇安彬祎吴莹莹桑红孔庆涛. 环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子信号通路在银屑病发病中的作用[J]. 中华皮肤科杂志, 2024, 0(3): 20230394-e20230394.
[4]	朱婷婷张学军. 阿普米司特在斑块状银屑病治疗中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230448-e20230448.
[5]	郝丹王怡怡肖月闫薇李薇. [开放获取] 特殊部位银屑病系统治疗临床研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230190-e20230190.
[6]	姚我汪慧英. [开放获取] 拉那利尤单抗治疗遗传性血管性水肿临床试验的系统综述[J]. 中华皮肤科杂志, 2024, 0(3): 20230378-e20230378.
[7]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[8]	王诗琪王爱平李航李若瑜. 趾甲银屑病与指甲银屑病的皮肤镜特征比较[J]. 中华皮肤科杂志, 2024, 57(2): 161-165.
[9]	张倩张金娥郭森宋璞高琳李春英. CO2点阵激光联合氟尿嘧啶/复方倍他米松注射液导入治疗白癜风的临床观察[J]. 中华皮肤科杂志, 2024, 57(1): 34-38.
[10]	刘元香梁源赵欣荣孙玉娟马琳徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852.
[11]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[12]	付丹丹李佳林付修宇张芯育胡华宋向凤田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844.
[13]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[14]	王俊霞郭伟楠陈慧郝军峰李冰卫静宜赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765.
[15]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.

生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展

Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

Metrics

本文评价

推荐阅读 10